The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma DOI Creative Commons

Yixin Ding,

Shasha Wang, Zhenkang Qiu

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Oct. 31, 2023

Systemic therapy remains the primary therapeutic approach for advanced hepatocellular carcinoma (HCC). Nonetheless, its efficacy in achieving control of intrahepatic lesions is constrained. Hepatic arterial infusion chemotherapy (HAIC) a that combines localized treatment with systemic antitumor effects, which aim to effectively manage progression cancerous within liver, particularly patients portal vein tumor thrombosis (PVTT). Combining HAIC anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb) immunotherapy anticipated emerge as novel aimed at augmenting response inside site and prolonged survival advantages. In order assess effectiveness, safety, applicability various modalities address potential molecular mechanisms underlying HAIC-sensitizing immunotherapy, we reviewed literature about combination anti-PD-1 mAb therapies.

Language: Английский

Hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib plus PD-1 inhibitors in hepatocellular carcinoma patients with tumor thrombosis in the inferior vena cava and/or right atrium DOI
Yidan Lou, Xiaoling Zhang, Pengfei Sun

et al.

Academic Radiology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Citations

3
Hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis DOI

Jiahui Yu,

Yong Li, Junsheng Yu

et al.

European Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 51(3), P. 109573 - 109573

Published: Jan. 6, 2025

Language: Английский

Citations

0
The Prognostic Value of CRP/Alb Ratio in Predicting Overall Survival for Hepatocellular Carcinoma Treated with Transcatheter Intra-Arterial Therapy Combined with Molecular-Targeted Agents and PD-1/PD-L1 Inhibitors DOI Creative Commons
Xiaoyu Huang, Gang Peng,

Yaqing Kong

et al.

Journal of Inflammation Research, Journal Year: 2025, Volume and Issue: Volume 18, P. 203 - 217

Published: Jan. 1, 2025

Purpose: This study aimed to evaluate the prognostic value of C-reactive protein albumin (CRP/Alb) ratio in hepatocellular carcinoma (HCC) treated with transcatheter intra-arterial therapy combined molecular targeted agents (MTAs) and programmed cell death 1 (PD-1)/programmed death-ligand (PD-L1) inhibitors. Methods: Medical records 271 consecutive patients HCC receiving this combination China between 2019 2023 were retrospectively analyzed. Prognostic factors for progression-free survival (PFS) overall (OS) identified using univariate multivariate Cox regression analyses. The discriminatory capability inflammation-based scores—including CRP/Alb ratio, alpha-fetoprotein immunotherapy (CRAFITY) score, modified Glasgow score (mGPS), platelet-lymphocyte (PLR), systemic immune-inflammation index (SII)—was assessed area under curve (AUC). Results: A total 133 met inclusion criteria. optimal cutoff binary classification predicting OS, as determined X-tile software, was 0.02. Multivariate analysis (hazard [HR] = 2.61, p < 0.001), tumor size (HR 2.45, 0.018), extrahepatic metastases 1.93, 0.015) independent predictors OS. For PFS, significant included Eastern Cooperative Oncology Group Performance Status 1.55, 0.033) macrovascular invasion 1.48, 0.046). Patients higher ratios more likely experience fever fatigue. demonstrated significantly AUCs than PLR SII at 24 months (all 0.05) showed comparable CRAFITY mGPS 12, 24, 36 months. Conclusion: is a valuable marker OS treatment-related adverse events MTAs PD-1/PD-L1 can be used simple reliable biomarker assessing prognosis guiding patient selection clinical practice. Keywords: transarterial chemoembolization, hepatic artery infusion chemotherapy, therapy, immunotherapy, inflammation,

Language: Английский

Citations

0
Comparing PD‐L1 and PD‐1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single‐center, real‐world study DOI

Minrui He,

Wa Xie,

Ze Yuan

et al.

International Journal of Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Abstract With the rise of anti‐vascular endothelial growth factor antibody and programmed cell death‐ligand 1 (PD‐L1) regimens, particularly bevacizumab atezolizumab, as first‐line treatments for advanced hepatocellular carcinoma (HCC), there is a need to explore PD‐L1 death inhibitors in combination therapies unresectable HCC (uHCC). Integrating systemic with locoregional approaches also emerging potent strategy. This study compares outcomes atezolizumab (PD‐L1 inhibitor) sintilimab (programmed or its biosimilar, combined hepatic arterial interventional (HAIT) uHCC patients. From January 2020 September 2023, retrospective analysis was conducted on 138 patients at Sun Yat‐sen University Cancer Center. The cohort included 69 treated (Bev/Ate) biosimilar (Bio/Sin), HAIT. propensity score matching employed further efficacy safety. median progression‐free survival (mPFS) 13.8 months Bev/Ate group 10.0 Bio/Sin ( p = 0.188). showed significantly longer intrahepatic mPFS (HR 0.381; 95% confidence interval 0.176–0.824; .018) higher overall response rates compared (60.87% vs. 31.88%, .001; 69.57% 49.28%, .024) based Response Evaluation Criteria Solid Tumors v1.1 modified criteria. Treatment‐related adverse events were similar between groups > .050). Combining alongside HAIT provided PFS However, atezolizumab‐bevacizumab superior control rates, warranting validation.

Language: Английский

Citations

0
PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study DOI Creative Commons

Zhaoqian He,

Hua Chen, Liang Chen

et al.

ImmunoTargets and Therapy, Journal Year: 2025, Volume and Issue: Volume 14, P. 51 - 63

Published: Jan. 1, 2025

To compare the clinical outcomes of different systemic therapies, specifically PD(L)1 inhibitors plus Lenvatinib versus Atezolizumab Bevacizumab, when combined with hepatic arterial infusion chemotherapy (HAIC) based on FOLFOX regimen (oxaliplatin, fluorouracil, and leucovorin) as first line treatment for unresectable hepatocellular carcinoma. This real-world retrospective study enrolled 294 patients HCC. All received HAIC in combination either (PLEN-HAIC) or Bevacizumab (AT-HAIC). Propensity score matching (PSM) was performed to balance patient characteristics. The overall response rate (ORR), progression-free survival (PFS), (OS) were compared. After PSM, 80 130 AT-HAIC PLEN-HAIC, respectively. No significant differences found ORR between PLEN-HAIC groups (50.0% vs 40.0% per RECIST, p = 0.202; 60.0% 57.7% mRECIST, 0.853). Both showed similar disease control rates. Median PFS 14.3 months 8.8 (p 0.018). OS significantly better group 0.045, both not reached). Subgroup analysis revealed that a compared PDL1 0.023). offers benefits over advanced Given its remarkable efficacy, could be promising first-line option

Language: Английский

Citations

0
Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis DOI Creative Commons
Lingling Zhao, Cheng Xu, Jiewen Deng

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: Feb. 12, 2025

Background Hepatic arterial infusion chemotherapy (HAIC) is increasingly recognized as a primary treatment option for patients with unresectable hepatocellular carcinoma (uHCC), providing focused localized tumors. The combination of lenvatinib, multikinase inhibitor, PD-1 inhibitors has demonstrated significant survival benefits in HCC. This meta-analysis aims to assess whether the integration HAIC lenvatinib and (referred HAIC-L-P group) leads better effectiveness security compared alone (L-P uHCC. Methods An exhaustive search literature was conducted, including PubMed, Cochrane Library, Embase, ClinicalTrials.gov, Web Science, from start each database until September 2024, ensure thorough up-to-date compilation relevant studies. Extract data on outcome measures such overall (OS), progression-free (PFS), objective response rate (ORR), disease control (DCR), adverse events (AEs). Subsequently, meta-analyses were performed using RevMan 5.4 quantitatively evaluate aggregated effect regimen versus L-P alone. Results In our systematic eight retrospective cohort studies, markedly enhanced OS, an HR 0.54 (95% CI: 0.45-0.64; p &lt; 0.00001), 1-year 2-year OS rates. Superior PFS also observed group, 0.64 0.55-0.75; 0.0001), higher Response rates ORR risk ratio 2.15 1.84-2.50; 0.00001) DCR 1.28 1.20-1.43; 0.0001). AEs classified grade 3 or above elevated notable ratios vomiting, AST, ALT, thrombocytopenia, neutropenia, hyperbilirubinemia. No life-threatening reported. Conclusion correlated tumor responses prolonged survival, alongside manageable effects, indicating its potential viable therapeutic strategy individuals afflicted Systematic review registration https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42024594109.

Language: Английский

Citations

0
Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review DOI Creative Commons
Ying Wu, Zhimin Zeng,

Shuanggang Chen

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 3, 2025

Background Hepatic arterial infusion chemotherapy (HAIC) has emerged as a promising treatment for unresectable hepatocellular carcinoma (HCC). However, the safety profiles of HAIC and its various combination therapies remain to be systematically evaluated. Methods We searched PubMed, Embase, Cochrane Library, Web Science databases from inception November 2024. Studies reporting adverse events (AEs) monotherapy or in HCC were included. The severity frequency AEs analyzed according different protocols. Results A total 58 studies (11 prospective, 47 retrospective) demonstrated relatively mild toxicity, primarily affecting hepatobiliary (transaminase elevation 53.2%, hypoalbuminemia 57.2%) hematological systems (anemia 43.0%, thrombocytopenia 35.2%). with targeted therapy showed increased events, including characteristic reactions like hand-foot syndrome (48.0%) hypertension (49.9%). combined targeted, immunotherapy exhibited highest reaction rates (neutropenia 82.9%, transaminase 97.1%), while anti-angiogenic favorable profile. Prospective consistently reported higher incidence than retrospective studies, suggesting potential underreporting clinical practice. Conclusions Different HAIC-based regimens exhibit distinct requiring individualized management approaches. propose comprehensive framework patient selection, monitoring strategies, AE management. These recommendations aim optimize outcomes minimizing impacts on quality life.

Language: Английский

Citations

0
Future perspectives on immunotherapy for hepatocellular carcinoma DOI Creative Commons
Landon L. Chan, Stephen L. Chan

Therapeutic Advances in Medical Oncology, Journal Year: 2025, Volume and Issue: 17

Published: Jan. 1, 2025

In recent years, several global phase III trials have shown that combinations of immune checkpoint inhibitors (ICIs) offer superior efficacy and survival compared to multi-kinase inhibitors, establishing them as the gold standard for treating patients with advanced hepatocellular carcinoma (HCC). This success has led investigations into expanding use immunotherapy various other settings populations, including neoadjuvant adjuvant therapies, decompensated liver function those awaiting transplantation. Despite its proven efficacy, a significant number still develop resistance immunotherapy, highlighting need innovative strategies address this challenge. Approaches aimed at enhancing tumour immunogenicity, such combining transarterial chemoembolization or radiation show promise. Additionally, novel immunotherapeutics – triplet therapy, bispecific antibodies, adoptive T-cell therapy cancer vaccines are in early development HCC. These agents demonstrated potential synergistic effects existing ICIs, initial studies yielding positive outcomes. review, we our future perspective on emphasizing emerging indications, combination new immunotherapeutic agents. Overall, HCC is brimming extraordinary potential, set transform treatment landscape redefine possibilities managing challenging disease.

Language: Английский

Citations

0
Matching-adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma DOI Creative Commons
Yimin Zhang, Xintong Wu, Junzhe Yi

et al.

Liver Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 25

Published: April 22, 2025

Introduction: Previous phase 3 FOHAIC-1 study demonstrated that hepatic arterial infusion chemotherapy (HAIC) of FOLFOX regimen displayed favorable outcomes in advanced hepatocellular carcinoma (HCC) patients, including those with high-risk features (main portal tumor invasion and > 50% liver infiltration). This aimed to compare the treatment efficacy HAIC-FOLFOX versus atezolizumab-bevacizumab HCC patients. Methods: Individual patient data from Chinese aggregate global IMbrave150 were used conduct an anchored matching-adjusted indirect comparison (MAIC). Hazard ratios (HR) restricted mean survival times (RMST) calculated assess differences. Landmark analysis was performed evaluate time-sensitive effects, simulated (STC) conducted as sensitivity analysis. Rates treatment-related adverse events (TRAEs) TRAE-related discontinuations also compared. Results: After matching baseline characteristics, HAIC showed a numerical OS benefit (HR 0.57, 95% CI, 0.30–1.08) similar PFS 0.79, 0.43–1.47) compared overall population. In significantly improved 0.30, 0.12–0.72) 2.89-month longer RMST (95% 0.15–5.64 months). Additionally, superior 0.25, 0.10–0.64) 2.88-month over 0.90–4.86). group revealed associated significant improvements both 0.32, 0.13–0.79) 0.24, 0.09–0.63) during 0–12 months following initiation. Sensitivity using STC yielded consistent results. lower rates grade 3-4 TRAEs discontinuation population group. Conclusion: provided benefits safety profile

Language: Английский

Citations

0
Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review DOI Creative Commons
Xing Lv, Pengbo Zhang, Erlei Zhang

et al.

World Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 23(1)

Published: April 26, 2025

Hepatocellular carcinoma (HCC) is a prevalent and lethal cancer, often diagnosed at advanced stages where traditional treatments such as surgical resection, liver transplantation, locoregional therapies provide limited benefits. Hepatic arterial infusion chemotherapy (HAIC) has emerged promising treatment modality for HCC, enhancing anti-tumor efficacy through targeted drug delivery while minimizing systemic side effects. However, the heterogeneous nature of HCC leads to variable responses HAIC, highlighting necessity reliable predictive indicators tailor personalized strategies. This review explores factors influencing HAIC success, including patient demographics, tumor characteristics, biomarkers, genomic profiles, imaging techniques radiomics deep learning models. Additionally, synergistic potential combined with immunotherapy molecular examined, demonstrating improved survival outcomes. Prognostic scoring systems nomograms that integrate clinical, molecular, data are discussed superior tools individualized prognostication compared staging systems. Understanding these predictors essential optimizing quality life patients HCC. Future research directions include large-scale prospective studies, integration multi-omics data, advancements in artificial intelligence refine models further personalize approaches.

Language: Английский

Citations

0